TriSalus Life Sciences, Inc.
NASDAQ:TLSIMedical - Devices
+$0.02 today
- Market cap
- $134.20M
- Beta
- 0.49
- P/E (TTM)
- -7.4
- EPS (TTM)
- -$0.53
Volume 0.36M
Average 0.38M
Returns on capital
TriSalus Life Sciences, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
115.8%
avg 136.1%
ROIC
-112.3%
avg -101.9%
ROA
-111.0%
avg -195.6%
Analysis
ROE is currently the strongest return metric at 115.8% versus its period average of 136.1%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Mary T. Szela | Chief Executive Officer, President & Director | USD 769.84K | 63 | 1.07M | 2.84% |
Jennifer L. Stevens | Chief Regulatory, Quality and Therapeutics Officer | USD 630K | 64 | — | — |
David Patience | Chief Financial Officer | USD 585.33K | 40 | 261.11K | 0.69% |
Richard Marshak | Chief Commercial Officer | USD 564.47K | 67 | 127.99K | 0.34% |
Richard Marshall | Chief Medical Officer | — | — | — | — |
Andrea Marasso | Vice President of Marketing | — | — | — | — |
Bryan F. Cox | Chief of Research | — | 64 | 162.81K | 0.43% |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Oct 5, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
12
$3.61M
Sells
18
$139,921.67
Net Transaction Value
+$3.47M
Net buying
Most Active
Marshak Richard
5 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Oct 5, 26Oct 5, 2026 | Stevens Jennifer Direct | Sell | $1.4K$1,387.24 |
| Oct 5, 26Oct 5, 2026 | Marshak Richard Direct | Sell | $1.4K$1,426.75 |
| Oct 5, 26Oct 5, 2026 | Cox Bryan F. Direct | Sell | $1.3K$1,299.44 |
| May 15, 26May 15, 2026 | Stansky Michael P Direct | Buy | $1M$1,025,000.00 |
| May 15, 26May 15, 2026 | Gordon Gary B. Direct | Buy | $24.6K$24,600.00 |
| May 15, 26May 15, 2026 | Patience David Direct | Buy | $17.3K$17,253.00 |
| May 15, 26May 15, 2026 | Szela Mary T Direct | Buy | $102.8K$102,776.38 |
| May 15, 26May 15, 2026 | Marshak Richard Direct | Sell | $1.4K$1,449.81 |
| May 15, 26May 15, 2026 | Wahlstrom Mats Direct | Buy | $151.8K$151,800.00 |
| May 15, 26May 15, 2026 | Stansky Michael P Indirect | Buy | $500K$500,000.00 |
1–10 of 30
Summary
Insiders reported 12 buys worth $3.61M and 18 sells worth $139,921.67 over the last 12 months. That adds up to net buying of $3.47M. Marshak Richard was the most active insider with 5 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +53.9% | +27.0% (5yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at +53.9% over three years. Forward estimates point to Revenue at +27.0% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does TriSalus Life Sciences, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about TLSI's management, answered from reported figures.
Who manages TLSI?
TriSalus Life Sciences, Inc. (TLSI) lists 7 active executives. The top listed executive is Richard Marshak, Chief Commercial Officer.
Are TLSI insiders buying or selling?
Recent insider activity shows net buying of $32.98M.
Continue the stock analysis
Jump to another research area for this company.